BioSpace News Archive

Drug Development

Taiho Oncology Announces Presentation of Phase 2 Data for Futibatinib (TAS-120) in Advanced Intrahepatic Cholangiocarcinoma at Virtual AACR Annual Meeting 2021

Taiho Oncology, Inc. announced efficacy and safety results from the Phase 2 FOENIX-CCA2 trial, a single-arm multicenter Phase 2 study evaluating futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements including gene fusions who have failed at least one line of therapy.

April 11, 2021
·
6 min read
Drug Development

Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual

First product candidate found to be effective in non-polyp patients in addition to polyp patients in a clinical trial, based on 100% of patients in both groups achieving SNOT-22 MCID at week 24 with LYR-210 (7500µg group)

April 11, 2021
·
9 min read